Peptide clinical trials that are recruiting

  • By Reed Calder
  • Last reviewed Nov 16, 2026
  • Every record opened by hand

The short answer

On November 13, 2026, ClinicalTrials.gov listed 50 recruiting, not-yet-recruiting or enrolling-by-invitation trials of the compounds on this site that we could verify. On November 15, 2026, we added 4 kisspeptin, 3 NAD+, 9 glutathione and 29 oxytocin trials, and on November 16 one gonadorelin and 22 triptorelin trials, so the list has 118. The largest groups are oxytocin outside labor and delivery (29), triptorelin (22), thymosin alpha-1 (17) and cagrilintide (12). Glutathione has 9, cerebrolysin 8, kisspeptin 4 and NAD+ 3. One tests BPC-157: 30 people recovering from shoulder surgery, starting in January 2027. One tests retatrutide, and none tests KPV, CJC-1295, ipamorelin or Semax. Eight records from a sponsor we couldn’t verify are listed apart.

A registered trial tells you that a study is planned or running, not what it found. This page lists the trials that are open or about to open, what each one tests, who runs it, how big it is and where the registry record is. We opened every record ourselves, kept the ones that name the compound as a treatment, and set aside the ones we couldn’t verify. Each registry link lists the sites and who can take part. We don’t give contact details or help anyone enroll. Trials that are running but no longer recruiting are on the in-progress page.

How to read the list

  • Recruiting: the sponsor says it is looking for participants now, whether or not anyone has joined yet.
  • Not yet recruiting: the trial is registered but not looking for participants yet.
  • Enrolling by invitation: the study team picks participants from a group it has already chosen. You can’t sign up.

Primary completion is when the last person is examined or treated for the main result. Being in a trial doesn’t make a compound safe or effective, and a registry entry doesn’t say what a trial found (Health Canada, 2026; ClinicalTrials.gov definitions).

Trials we could verify

118 trials, grouped by compound. Registry data as of Nov 13, 2026, except the kisspeptin, NAD+, glutathione and oxytocin trials, which were added on Nov 15, 2026, and the gonadorelin and triptorelin trials, added on Nov 16, 2026. Every record opened by hand; sponsor names are as the registry spells them, except that where the registry lists a person as sponsor we show their hospital.

BPC-157

One trial. A second BPC-157 record is in the table of records we couldn’t verify, below. What the research shows.

Recruiting and not-yet-recruiting trials of BPC-157, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07803250 BPC-157 or saline, injected under the skin once a day for 90 days after rotator cuff repair surgery, to see whether it helps tendon healing and recovery. Phase 1, 30 people. Randomized, placebo, blinded. University of Arkansas. 1 site, United States. Not yet recruiting. Starts Jan 2027 (est.); primary completion Aug 2027 (est.). Record updated Sep 2026.

Thymosin beta-4

NL005 is a recombinant thymosin beta-4 from Beijing Northland Biotech. TB-500, a different and shorter molecule, has no trial we could verify. What the research shows.

Recruiting and not-yet-recruiting trials of Thymosin beta-4, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07586865 NL005, a lab-made thymosin beta-4 for injection, against placebo in people with an acute heart attack. Phase 2, 189 people. Randomized, placebo, blinded. Beijing Northland Biotech. Co., Ltd.. 1 site, China. Not yet recruiting. Starts May 2026 (est.) (date has passed); primary completion Aug 2027 (est.). Record updated May 2026.

Tesamorelin

Tesamorelin is FDA-approved for deep belly fat in adults with HIV. Both trials test other uses. What the research shows.

Recruiting and not-yet-recruiting trials of Tesamorelin, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT06554717 Tesamorelin or placebo, alongside exercise, in people with HIV and frailty, to see whether it improves physical function. Phase 2, 100 people. Randomized, placebo, blinded. Massachusetts General Hospital. 2 sites, United States. Recruiting. Started Jul 2025; primary completion Jun 2028 (est.). Record updated May 2026.
NCT03150511 Tesamorelin after a peripheral nerve injury, to see whether it improves recovery of function. Phase 2, 36 people. Randomized, blinded. Johns Hopkins University. 1 site, United States. Recruiting. Started Jun 2018; primary completion Dec 2027 (est.). Record updated Nov 2026.

SS-31 (elamipretide)

Elamipretide is the drug name for SS-31. What the research shows.

Recruiting and not-yet-recruiting trials of SS-31 (elamipretide), from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07531251 Elamipretide (SS-31) or placebo in people with Barth syndrome, a rare inherited mitochondrial disease (4TAZPower). Phase 4, 48 people. Randomized, placebo, blinded. Stealth BioTherapeutics Inc.. 4 sites in 4 countries and regions. Recruiting. Started Jul 2026; primary completion Sep 2029 (est.). Record updated Nov 2026.
NCT07927972 How the body handles elamipretide injected under the skin, and its safety, in children with Barth syndrome. One group, no comparison. Phase 1, 6 people. One group, open label. Stealth BioTherapeutics Inc.. No site listed yet. Not yet recruiting. Starts Nov 2026 (est.); primary completion May 2027 (est.). Record updated Nov 2026.
NCT07275424 Elamipretide in healthy older adults, with physical function as the outcome. One group, no comparison. Phase 2, 30 people. One group, open label. David Marcinek. 1 site, United States. Recruiting. Started Nov 2025; primary completion Mar 2026 (est.) (date has passed). Record updated Dec 2025.

MK-677 (ibutamoren) and LUM-201

LUM-201 is the same compound as MK-677, in development for children with growth hormone deficiency. All four trials are Lumos Pharma’s. What the research shows.

Recruiting and not-yet-recruiting trials of MK-677 (ibutamoren) and LUM-201, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT06948214 LUM-201, the oral growth hormone secretagogue also known as ibutamoren or MK-677, against matched placebo capsules in children with growth hormone deficiency. Phase 3, 150 people. Randomized, placebo, blinded. Lumos Pharma. 55 sites in 8 countries and regions. Recruiting. Started May 2026; primary completion Dec 2027 (est.). Record updated Oct 2026.
NCT07754045 LUM-201 plus semaglutide against semaglutide plus placebo in older adults with obesity. Phase 2, 202 people. Randomized, placebo, blinded. Lumos Pharma. No site listed yet. Not yet recruiting. Starts Feb 2027 (est.); primary completion Feb 2028 (est.). Record updated Aug 2026.
NCT05796440 Long-term safety of LUM-201 in children with growth hormone deficiency who finished an earlier LUM-201 trial (OraGrowtH211). Phase 2, 60 people. One group, open label. Lumos Pharma. 7 sites in Australia, United States. Enrolling by invitation. Started Aug 2023; primary completion Mar 2028 (est.). Record updated Feb 2024.
NCT07129759 Long-term safety extension of LUM-201 in children with growth hormone deficiency. Phase 3, 150 people. One group, open label. Lumos Pharma. No site listed yet. Not yet recruiting. Starts Feb 2027 (est.); primary completion Feb 2030 (est.). Record updated Jul 2026.

GHK-Cu, AHK-Cu and epitalon

One early study applies a serum of five peptides to the skin. It names all three compounds. What the research shows.

Recruiting and not-yet-recruiting trials of GHK-Cu, AHK-Cu and epitalon, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07888595 A skin serum of five peptides (GHK-Cu, AHK-Cu, epitalon, PGP and CLV), applied to marked skin sites and compared with untreated sites, in a study that also gives other agents by mouth, to see whether skin “biological age” changes. Early phase 1, 48 people. One group, open label. Frontiers in Bioscience Research Institute and Aging. 1 site, United States. Enrolling by invitation. Started Oct 2026 (est.); primary completion Oct 2028 (est.). Record updated Oct 2026.

Kisspeptin

Three of the four records call the compound kisspeptin 112-121, which is kisspeptin-10 (UniProt, 2026). Three are at Massachusetts General Hospital and one is at Imperial College London. None compares kisspeptin with a standard treatment. A fifth recruiting record, a Polish study that only measures kisspeptin in blood, is left out. Pulled and opened by hand on Nov 15, 2026. What the research shows.

Recruiting and not-yet-recruiting trials of Kisspeptin, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT02081924 Kisspeptin or saline given under the skin by a pump for 8 days a month, at three dose rates (0.1, 0.3 and 1.0 nmol/kg per hour), in healthy adults aged 18 to 60. The main measure is luteinizing hormone (LH). No drug phase, 76 people. Randomized, placebo, blinded. Imperial College London. 1 site, United Kingdom. Recruiting. Started Apr 2014; primary completion Nov 2027 (est.). Record updated Sep 2024.
NCT05896293 Kisspeptin (listed as kisspeptin 112-121) given under the skin in pulses every 60 to 240 minutes for two weeks, plus one leuprolide injection, in men and women with idiopathic hypogonadotropic hypogonadism, a condition in which the brain doesn’t send the hormone signal that switches on the testes or ovaries. The main measure is the size of the LH pulses; the team also looks at whether women release eggs. Phase 2, 36 people. One group, open label. Massachusetts General Hospital (the registry lists the principal investigator as sponsor). 1 site, United States. Recruiting. Started Feb 2023; primary completion May 2028 (est.). Record updated Jul 2026.
NCT07224438 Kisspeptin (listed as kisspeptin 112-121) given under the skin in pulses about every 90 minutes for two weeks, in women aged 18 to 45 with hypothalamic amenorrhea, absent periods linked to a low hormone signal from the brain. The main measure is the size of the LH pulses; the team also looks at whether the ovaries release eggs. Phase 2, 20 people. One group, open label. Massachusetts General Hospital (the registry lists the principal investigator as sponsor). 1 site, United States. Recruiting. Started Dec 2025; primary completion May 2030 (est.). Record updated Jul 2026.
NCT07224490 A single intravenous dose of kisspeptin, used as a test and not as a treatment, to compare the LH response in people aged 18 to 60 with and without post-COVID-19 syndrome. Phase 1, 40 people. One group, open label. Massachusetts General Hospital (the registry lists the principal investigator as sponsor). 1 site, United States. Recruiting. Started Mar 2026; primary completion May 2030 (est.). Record updated Jul 2026.

NAD+

Three of the five records that name NAD+ and are open or about to open: an injection for children with weak heart pumping, an oral supplement, and a comparison of two injected forms. Two others test NAD+ precursors by mouth (NMN, nicotinamide riboside), which are different molecules, so we left them out. Pulled and opened by hand on Nov 15, 2026. What the research shows.

Recruiting and not-yet-recruiting trials of NAD+, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07839130 Injectable NAD+ at two dose levels, or placebo, given into a vein once a day for 7 days alongside standard care, in children under 18 hospitalized with weak heart pumping (cardiac dysfunction). The main measure is the heart’s ejection fraction after 4 weeks (PEDI-NAD). Phase 2, 180 people. Randomized, placebo, blinded. Beijing Children's Hospital. 1 site, China. Not yet recruiting. Starts Oct 2026 (est.) (date has passed); primary completion Apr 2028 (est.). Record updated Sep 2026.
NCT07692633 An oral NAD+ supplement against placebo, two capsules a day with breakfast, in healthy adults aged 40 to 65. The main measure is the change in NAD+ in whole blood from the start to day 56. No drug phase, 80 people. Randomized, placebo, blinded. Reus Research. 1 site, Canada. Recruiting. Started Oct 2026; primary completion Mar 2027 (est.). Record updated Nov 2026.
NCT06919328 Injected nicotinamide riboside (a vitamin B3 form sold as Niagen) against injected NAD+, 100 mg each, by different injection routes, in healthy adults aged 40 to 65. The main measures are pain and discomfort at the injection. No drug phase, 70 people. Randomized, placebo, blinded. Nutraceuticals Research Institute, with ChromaDex. 1 site, United States. Recruiting. Started Oct 2024; primary completion Apr 2025 (est.) (date has passed). Record updated Apr 2025.

Glutathione

Nine of the eleven records that name glutathione and are open or about to open. Three, from two clinics, test a stem cell and exosome product plus glutathione against glutathione alone. We left out two: a steroid trial in drug-induced liver injury that lists glutathione only as standard care in both groups, and a soccer trial of S-acetyl glutathione, a modified form. Pulled and opened by hand on Nov 15, 2026. What the research shows.

Recruiting and not-yet-recruiting trials of Glutathione, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07595705 Injected vitamin C with glutathione against surgical removal, for dark gum pigmentation (gingival hyperpigmentation). Phase 2, 30 people. Randomized, open label. Cairo University. 1 site, Egypt. Recruiting. Started Aug 2025; primary completion Jan 2027 (est.). Record updated May 2026.
NCT06620523 Coenzyme Q10 (1,200 mg) with glutathione (1,000 mg), by mouth each day, or matching placebo, starting the day before heart surgery with a heart-lung machine, to see whether it prevents acute kidney injury. Phase 2, 242 people. Randomized, placebo, blinded. George Washington University. 1 site, United States. Recruiting. Started Jul 2024; primary completion Jun 2027 (est.). Record updated Oct 2026.
NCT06896422 Glutathione added to a PD-1 antibody plus platinum chemotherapy, against the same treatment without it, in advanced non-small cell lung cancer. The main measures are progression-free survival and response rate. Phase 1, 80 people. Randomized, open label. The First Affiliated Hospital of Zhengzhou University. 1 site, China. Recruiting. Started Jun 2025; primary completion Dec 2026 (est.). Record updated Aug 2025.
NCT07379216 A liquid sachet of vitamin C and glutathione, one a day for 12 weeks, against a placebo sachet, for skin tone and spots in adults aged 18 to 65. No drug phase, 30 people. Randomized, placebo, blinded. TCI Co., Ltd.. 1 site, Taiwan. Recruiting. Started Jan 2026; primary completion May 2026 (est.) (date has passed). Record updated Feb 2026.
NCT07202156 A skin solution of 10% tranexamic acid and 2% reduced glutathione applied with ultrasound or without it, in melasma. Both groups get the glutathione; the test is whether ultrasound improves delivery. No drug phase, 35 people. Randomized, blinded. The First Affiliated Hospital with Nanjing Medical University. 1 site, China. Recruiting. Started Oct 2024; primary completion Feb 2026 (est.) (date has passed). Record updated Nov 2025.
NCT07448415 Glutathione applied to the skin during microneedling, alone or with oral tranexamic acid, against oral tranexamic acid alone, in women with melasma. Phase 2/3, 42 people. Randomized, open label. Assiut University. No site listed yet. Not yet recruiting. Starts Feb 2026 (est.) (date has passed); primary completion Feb 2027 (est.). Record updated Mar 2026.
NCT07622316 AdiaVita, a product made from umbilical cord blood stem cells and exosomes, plus glutathione by vein, against glutathione by vein alone, in people aged 3 and older with autism spectrum disorder. Glutathione is given in both groups. The main measure is the Autism Treatment Evaluation Checklist score. Phase 1, 100 people. Randomized, blinded. Greater Atlanta Integrative Pediatrics. 2 sites, United States. Recruiting. Started Jun 2026 (est.); primary completion Dec 2026 (est.). Record updated Jun 2026.
NCT07304440 The same umbilical cord blood product plus glutathione by vein, against glutathione by vein alone, in children aged 3 to 12 with autism. Glutathione is given in both groups. The main measure is the Autism Treatment Evaluation Checklist score. Phase 1, 100 people. Randomized, blinded. Adia Med of Winter Park LLC. 2 sites, United States. Recruiting. Started May 2026; primary completion Jun 2028 (est.). Record updated Sep 2026.
NCT07572890 The same umbilical cord blood product plus glutathione (by vein and as a skin spray), against glutathione alone and against placebo, in adults with chronic kidney disease. The main measures are estimated glomerular filtration rate and serum creatinine. Phase 1, 100 people. Randomized, placebo, blinded. Adia Med of Winter Park LLC. 1 site, United States. Recruiting. Started May 2026 (est.); primary completion Jan 2028 (est.). Record updated Jun 2026.

Oxytocin: mood, stress and autism

29 records give oxytocin outside labor and delivery, split into five tables below. Another 26 record oxytocin in labor, delivery and cesarean care, counted in the large-programs table and not listed. Five more with “oxytocin” in an intervention name are massage, device or measurement studies, and we left them out. Pulled and opened by hand on Nov 15, 2026. This first table is oxytocin added to therapy for PTSD, borderline personality disorder and schizophrenia, and tested in autism and in caregivers’ stress. What the research shows.

Recruiting and not-yet-recruiting trials: Oxytocin: mood, stress and autism, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT06194851 Nasal oxytocin (40 IU, taken before each therapy session) or saline spray added to brief cognitive-behavioral conjoint therapy for couples in which a veteran has post-traumatic stress disorder. The main measure is the change in PTSD diagnosis and severity. Phase 2, 240 people. Randomized, placebo, blinded. VA Office of Research and Development. 1 site, United States. Recruiting. Started Oct 2024; primary completion Sep 2028 (est.). Record updated May 2026.
NCT07551882 Nasal oxytocin (24 IU) or placebo spray together with self-compassion training in borderline personality disorder. The main measure is the Self-Compassion Scale. Phase 2, 80 people. Randomized, placebo, blinded. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. 1 site, Spain. Recruiting. Started Jan 2024; primary completion Jun 2026 (est.) (date has passed). Record updated Apr 2026.
NCT07265180 Oxytocin nasal spray (Syntocinon) at 24 IU or 48 IU, or placebo, alongside mindfulness-based group therapy in schizophrenia spectrum disorders. The main measure is the Brief Negative Symptom Scale. No drug phase, 120 people. Randomized, placebo, blinded. Charite University, Berlin, Germany. 1 site, Germany. Recruiting. Started Sep 2025; primary completion Nov 2026 (est.). Record updated Aug 2026.
NCT05864508 Nasal oxytocin once a day for 6 weeks in children aged 6 to 12 with autism and intellectual disability, to test whether the treatment can be given and monitored as planned. One group, no comparison. Phase 2, 30 people. One group, open label. University Hospital, Toulouse. 1 site, France. Not yet recruiting. Starts Jul 2023 (est.) (date has passed); primary completion Dec 2026 (est.). Record updated May 2023.
NCT06364228 Nasal oxytocin (12 IU or 24 IU) or placebo spray in women aged 50 and older who care for a person with dementia, with brain scans. The main measure is chronic stress level over the past 30 days. Phase 2, 32 people. Randomized, placebo, blinded. University of Nebraska. 1 site, United States. Recruiting. Started Dec 2026 (est.); primary completion Nov 2027 (est.). Record updated Nov 2026.

Oxytocin: arginine vasopressin deficiency

Arginine vasopressin deficiency, also called central diabetes insipidus, is a lack of the pituitary hormone vasopressin. Two research groups are testing whether nasal oxytocin helps people who have it.

Recruiting and not-yet-recruiting trials: Oxytocin: arginine vasopressin deficiency, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT06676774 Nasal oxytocin or placebo in adults with arginine vasopressin deficiency (also called central diabetes insipidus) and matched healthy controls, to see whether it changes emotion recognition and the cortisol rise after an acute stress test. Phase 2, 42 people. Randomized, placebo, blinded. University Hospital, Basel, Switzerland. 1 site, Switzerland. Recruiting. Started May 2025; primary completion Feb 2027 (est.). Record updated May 2025.
NCT06808516 Nasal oxytocin (24 IU) or placebo, for 7 days and as a single dose, in adults with arginine vasopressin deficiency and healthy controls. The main measures are the Arizona Sexual Experience Scale and the New Sexual Satisfaction Scale. Phase 2, 42 people. Randomized, placebo, blinded. University Hospital, Basel, Switzerland. 1 site, Switzerland. Recruiting. Started Jul 2025; primary completion Dec 2026 (est.). Record updated Oct 2025.
NCT04789148 Nasal oxytocin as a single dose (6 IU or 24 IU), or 6 IU three times a day for 2 weeks, against placebo, in adults with arginine vasopressin deficiency. The main measure is anxious behavior on a dot-probe task. Phase 1, 40 people. Randomized, placebo, blinded. Massachusetts General Hospital (the registry lists the principal investigator as sponsor). 1 site, United States. Recruiting. Started Sep 2025; primary completion Jun 2027 (est.). Record updated Oct 2026.

Oxytocin: pain, surgery and opioids

Intravenous and nasal oxytocin tested for pain and recovery after surgery, with opioid drugs, and for slowed breathing after opioids.

Recruiting and not-yet-recruiting trials: Oxytocin: pain, surgery and opioids, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07730294 Nasal oxytocin (TNX-1900) at a low dose (6 IU a day) or a high dose (24 IU a day), or a saline placebo, for pain after pituitary surgery. The main measures are pain scores and pain medicine use. Phase 2, 75 people. Randomized, placebo, blinded. Yale University. 1 site, United States. Recruiting. Started Nov 2026 (est.); primary completion Nov 2028 (est.). Record updated Nov 2026.
NCT06483659 An intravenous oxytocin infusion or placebo during minimally invasive hysterectomy under general anesthesia, to see whether it lowers opioid use and pain afterward. Phase 2, 152 people. Randomized, placebo, blinded. Brigham and Women's Hospital. 1 site, United States. Recruiting. Started Jun 2025; primary completion Dec 2027 (est.). Record updated Aug 2026.
NCT07430228 A single intravenous dose of oxytocin (26 micrograms) or placebo around total hip replacement, to see whether recovery is faster, measured by daily steps over 56 days. Phase 2, 80 people. Randomized, placebo, blinded. Wake Forest University Health Sciences. 1 site, United States. Enrolling by invitation. Started Dec 2026 (est.); primary completion Dec 2027 (est.). Record updated Oct 2026.
NCT07409753 Intravenous oxytocin (20 IU, in two 30-minute infusions) or placebo, to see whether it changes how nerve fibers in the skin respond to pressure after pulses of non-burning heat (microneurography). The main measure is the number of nerve fiber discharges. Phase 2, 60 people. Randomized, placebo, blinded. Wake Forest University Health Sciences. 1 site, Sweden. Recruiting. Started Oct 2025; primary completion Jun 2027 (est.). Record updated Nov 2026.
NCT05761860 Nasal oxytocin (48 IU) with oral oxycodone (2.5 mg or 5 mg), or either drug alone against placebo, in adults aged 45 to 85, to see whether oxytocin changes oxycodone’s abuse liability and pain relief. The main measure is subject-rated abuse liability. Early phase 1, 45 people. Randomized, placebo, blinded. University of Florida. 1 site, United States. Recruiting. Started Sep 2023; primary completion Dec 2026 (est.). Record updated May 2026.
NCT04218409 The same design in adults aged 21 to 45: nasal oxytocin (48 IU) with oral oxycodone (5 mg), each alone, or placebo. The main measure is subject-rated abuse liability. Early phase 1, 45 people. Randomized, placebo, blinded. University of Florida. 1 site, United States. Recruiting. Started Sep 2021; primary completion Dec 2026 (est.). Record updated Jan 2026.
NCT07902752 Nasal oxytocin (40 IU) or placebo spray to prevent opioid-induced slow or stopped breathing after surgery, in adults having bariatric surgery. The main measures are postoperative hypopnea and apnea events. Phase 2, 100 people. Randomized, placebo, blinded. George Washington University. No site listed yet. Not yet recruiting. Starts May 2027 (est.); primary completion Jul 2029 (est.). Record updated Oct 2026.

Oxytocin: experiments in healthy volunteers

Tests of brain activity and behavior in healthy adults, mostly men. Eight of the ten are from one university in China, and several show primary completion dates that have already passed.

Recruiting and not-yet-recruiting trials: Oxytocin: experiments in healthy volunteers, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07425938 Nasal oxytocin (24 IU), with or without a nasal decongestant, against placebo, in healthy men aged 18 to 30, to see how it changes brain activity in response to emotional pictures on fMRI and through which route. No drug phase, 120 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Jan 2026; primary completion Apr 2026 (est.) (date has passed). Record updated Feb 2026.
NCT07140237 Oxytocin by lingual spray (on and under the tongue) at 24 IU or 48 IU, atosiban (a drug that blocks oxytocin receptors) or placebo, in healthy men aged 18 to 35, to see whether it changes top-down attention on eye-movement tests. Early phase 1, 250 people. Not randomized, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Sep 2025 (est.); primary completion Dec 2025 (est.) (date has passed). Record updated Sep 2025.
NCT07093060 The same four groups (24 IU or 48 IU oxytocin by lingual spray, atosiban or placebo) in healthy men aged 18 to 35, to see whether oxytocin changes social attention, measured by eye fixation. Early phase 1, 250 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Jun 2025; primary completion Nov 2025 (est.) (date has passed). Record updated Jul 2025.
NCT07367672 Nasal oxytocin (24 IU), placebo spray or no spray in healthy adults aged 18 to 30, to see how belief and expectation change ratings of empathic pain, the pain felt when watching someone else in distress. No drug phase, 120 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 2 sites, China. Recruiting. Started Dec 2025; primary completion Feb 2026 (est.) (date has passed). Record updated Jan 2026.
NCT07559656 Nasal oxytocin (24 IU) or placebo before real-time fMRI neurofeedback training of the anterior insula, in healthy men aged 18 to 30. No drug phase, 80 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Apr 2026 (est.); primary completion Sep 2026 (est.) (date has passed). Record updated Apr 2026.
NCT07838493 A single 24 IU dose of oxytocin or of arginine vasopressin, or placebo, taken through the lining of the mouth with a lollipop-style product, in healthy adults aged 18 to 30, to see how they change attention to emotional faces. No drug phase, 120 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Sep 2026 (est.); primary completion Dec 2026 (est.). Record updated Sep 2026.
NCT07162584 Nasal oxytocin (24 IU) or placebo in healthy adults aged 18 to 35, to see how it changes responses to threat in a dynamic task, measured by escape success and flight distance. No drug phase, 80 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Sep 2025; primary completion Jan 2026 (est.) (date has passed). Record updated Oct 2025.
NCT07815496 Nasal oxytocin (24 IU) or placebo in healthy adults aged 18 to 35, to see how it changes fairness perception and related prosocial behavior. No drug phase, 80 people. Randomized, placebo, blinded. University of Electronic Science and Technology of China. 1 site, China. Recruiting. Started Sep 2026; primary completion Dec 2026 (est.). Record updated Sep 2026.
NCT06222749 Nasal oxytocin (24 IU of Syntocinon) or placebo in women aged 18 to 40, tested at two points of the menstrual cycle and on two kinds of birth-control pill, to see how oxytocin changes reward-related brain responses. No drug phase, 100 people. Randomized, placebo, blinded. International Research Training Group 2804. 1 site, Germany. Recruiting. Started Feb 2024; primary completion Dec 2026 (est.). Record updated Feb 2024.
NCT06248710 Nasal oxytocin (24 IU) or placebo spray, with or without a dog present, in healthy adults, to see whether either changes trust in a therapist. Phase 2/3, 176 people. Randomized, placebo, blinded. University of Basel (the registry lists the principal investigator as sponsor). 1 site, Switzerland. Recruiting. Started Jan 2024; primary completion Dec 2024 (est.) (date has passed). Record updated Nov 2024.

Oxytocin: weight, blood sugar, sleep and bone

Nasal or intravenous oxytocin for obesity in young people, blood sugar, sleep apnea and bone health in children with autism.

Recruiting and not-yet-recruiting trials: Oxytocin: weight, blood sugar, sleep and bone, from ClinicalTrials.gov, Nov 15, 2026
Registry record What it tests Design Sponsor, place and dates
NCT04551482 Nasal oxytocin (24 IU, four times a day for 12 weeks) or placebo in young people aged 10 to 18 with obesity. The main measure is body mass index. Phase 2, 54 people. Randomized, placebo, blinded. Massachusetts General Hospital. 1 site, United States. Recruiting. Started Jul 2021; primary completion Mar 2027 (est.). Record updated Nov 2026.
NCT06334172 Oxytocin infusion at 0.1 or 0.2 IU a minute, or placebo, in men aged 20 to 50, to see how it changes insulin secretion (C-peptide) at set blood sugar levels. No drug phase, 20 people. Randomized, placebo, blinded. University Hospital, Gentofte, Copenhagen. 1 site, Denmark. Recruiting. Started Jan 2024; primary completion Dec 2026 (est.). Record updated Apr 2024.
NCT03860233 Nasal oxytocin (40 IU) before sleep for 14 days, or placebo, in people with obstructive sleep apnea who use CPAP, to see whether it lowers the air pressure the machine needs. Phase 1, 40 people. Randomized, placebo, blinded. George Washington University (the registry lists the principal investigator as sponsor). 1 site, United States. Recruiting. Started Mar 2019; primary completion Dec 2026 (est.). Record updated May 2026.
NCT05754073 Nasal oxytocin (30 IU twice a day for 12 months) or placebo in children aged 6 to 18 with autism, followed by 6 months of open-label oxytocin for all. The main measure is the 12-month change in whole-body bone density, excluding the head. Phase 2, 96 people. Randomized, placebo, blinded. Massachusetts General Hospital (the registry lists the principal investigator as sponsor). 2 sites, United States. Recruiting. Started Aug 2023; primary completion Aug 2027 (est.). Record updated Mar 2026.

Gonadorelin

One trial: a randomized, placebo-controlled test of a GnRH pump (gonadorelin acetate under the skin) on cognition in people with Down syndrome. The other registry records that name gonadorelin use it as a test, have unknown status, were withdrawn or are finished, so we left them out. Pulled and opened by hand on Nov 16, 2026. What the research shows.

Recruiting and not-yet-recruiting trials of Gonadorelin, from ClinicalTrials.gov, Nov 16, 2026
Registry record What it tests Design Sponsor, place and dates
NCT04390646 A pulsatile GnRH pump (gonadorelin acetate under the skin) or a placebo pump, in people aged 16 to 50 with Down syndrome, to see whether it improves cognition. The main measure is cognition. Phase 2/3, 56 people. Randomized, blinded. Centre Hospitalier Universitaire Vaudois (the registry lists the principal investigator as sponsor). 1 site, Switzerland. Recruiting. Started Aug 2020; primary completion Dec 2028 (est.). Record updated Feb 2024.

Triptorelin: IVF and frozen embryo transfer

22 records test triptorelin itself, split into four tables below. We list a record when triptorelin, or a triptorelin brand, is the thing tested or the tested strategy names it as its drug. Another 17 open records name triptorelin only as one of several allowed background hormone drugs and are counted in the large-programs table; 20 more mention it only in a description, as part of an IVF protocol or one of several drug options, and we left them out. Pulled and opened by hand on Nov 16, 2026. This first table is IVF and frozen embryo transfer: triptorelin as the trigger that matures the eggs, as pretreatment before a frozen embryo transfer and as luteal support. Five of the twelve name triptorelin in the arm or intervention description rather than in the intervention name. What the research shows.

Recruiting and not-yet-recruiting trials: Triptorelin: IVF and frozen embryo transfer, from ClinicalTrials.gov, Nov 16, 2026
Registry record What it tests Design Sponsor, place and dates
NCT04064840 Triptorelin (Decapeptyl) 0.2 mg added to hCG to trigger egg maturation, against hCG with saline, in IVF; and triptorelin 0.1 mg or saline on the day of a frozen embryo transfer. The main measure is live birth. Phase 3, 784 people. Randomized, placebo, blinded. The University of Hong Kong. 1 site, China. Recruiting. Started Sep 2019; primary completion Sep 2024 (date has passed). Record updated May 2026.
NCT06150703 Triptorelin 0.2 mg to trigger egg maturation, followed by nasal nafarelin for luteal support, against hCG with vaginal progesterone, in IVF or ICSI. The main measure is live birth. Phase 3, 652 people. Randomized, open label. Assistance Publique - Hôpitaux de Paris. 1 site, France. Recruiting. Started Jun 2024; primary completion Sep 2027 (est.). Record updated Aug 2025.
NCT06763926 Subcutaneous triptorelin (200 mcg) against intranasal nafarelin (800 mcg) to trigger egg maturation before egg collection. The main measure is the number of mature (MII) eggs retrieved. Phase 4, 154 people. Randomized, open label. Fundacion Dexeus. 5 sites, Spain. Recruiting. Started Oct 2026; primary completion Jan 2028 (est.). Record updated Oct 2026.
NCT07696351 Long-acting triptorelin (a GnRH agonist) injected twice, 28 to 30 days apart, before a frozen embryo transfer, against routine hormone replacement alone, in women with deep infiltrating endometriosis. The main measure is clinical pregnancy. Phase 4, 120 people. Randomized, open label. Nanjing University (the registry lists the principal investigator as sponsor). 1 site, China. Recruiting. Started Aug 2025; primary completion Dec 2026 (est.). Record updated Jul 2026.
NCT07816562 Three ways to trigger egg maturation in women with low ovarian reserve: hCG alone, follitropin delta plus hCG, or triptorelin plus hCG. The main measure is the number of mature eggs. Phase 3, 126 people. Randomized, blinded. Fundación para la Investigación del Hospital Clínico de Valencia. 1 site, Spain. Recruiting. Started Sep 2024; primary completion Jul 2027 (est.). Record updated Sep 2026.
NCT07861399 A dual trigger (triptorelin acetate plus hCG) against hCG alone for final egg maturation in women aged 20 to 40 who respond normally to stimulation. The main measure is egg maturation. No drug phase, 100 people. Randomized, blinded. Al-Azhar University. 1 site, Egypt. Recruiting. Started Sep 2026; primary completion Aug 2028 (est.). Record updated Oct 2026.
NCT04356664 One or two injections of Decapeptyl 3 mg (triptorelin) before hormone replacement for a frozen embryo transfer, against hormone replacement alone, in women with endometriosis or adenomyosis. The main measure is clinical pregnancy. Phase 2/3, 180 people. Randomized, open label. Hopital Foch. 1 site, France. Recruiting. Started Mar 2021; primary completion Jun 2026 (est.) (date has passed). Record updated Jan 2026.
NCT07569289 A double trigger (triptorelin and hCG) against hCG alone in poor responders to IVF stimulation (POSEIDON groups 3 and 4). The main measure is the rate of mature (MII) eggs. Phase 2, 164 people. Randomized, blinded. Bedaya Hospital. 1 site, Egypt. Not yet recruiting. Starts Jun 2026 (est.) (date has passed); primary completion Dec 2027 (est.). Record updated May 2026.
NCT07569302 A modified dual trigger (hCG plus two successive triptorelin doses) against hCG alone in women who respond normally to IVF stimulation. The main measure is the rate of mature eggs. Phase 2, 196 people. Randomized, blinded. Bedaya Hospital. 1 site, Egypt. Not yet recruiting. Starts Jun 2026 (est.) (date has passed); primary completion Dec 2027 (est.). Record updated May 2026.
NCT07569315 Three successive doses of triptorelin against a single dose to trigger egg maturation in women who over-respond to IVF stimulation. The main measure is the rate of mature eggs. Phase 2, 190 people. Randomized, blinded. Bedaya Hospital. 1 site, Egypt. Not yet recruiting. Starts Jun 2026 (est.) (date has passed); primary completion Dec 2027 (est.). Record updated May 2026.
NCT07653282 A single injection of triptorelin 0.1 mg added to standard hormone therapy before a frozen embryo transfer, against standard therapy alone. The main measure is clinical pregnancy. Phase 1/2, 122 people. Randomized, blinded. Assiut University. 1 site, Egypt. Not yet recruiting. Starts Aug 2026 (est.) (date has passed); primary completion Aug 2027 (est.). Record updated Jun 2026.
NCT06913075 Triptorelin acetate 3.75 mg, two doses 30 days apart, with or without letrozole, before a frozen embryo transfer in women with adenomyosis; the groups cross over. The main measure is ongoing pregnancy. No drug phase, 700 people. Randomized, open label. Indira IVF Hospital Pvt Ltd. 1 site, India. Not yet recruiting. Starts Jun 2026 (est.) (date has passed); primary completion Jul 2026 (est.) (date has passed). Record updated Jan 2026.

Triptorelin: breast cancer and protecting the ovaries

Triptorelin given during chemotherapy to protect the ovaries, and an elacestrant trial in which triptorelin provides the ovarian suppression.

Recruiting and not-yet-recruiting trials: Triptorelin: breast cancer and protecting the ovaries, from ClinicalTrials.gov, Nov 16, 2026
Registry record What it tests Design Sponsor, place and dates
NCT05328258 Triptorelin (11.25 mg or 3.75 mg into a muscle) or placebo during chemotherapy to protect ovarian function in girls and women with breast cancer, leukemia, lymphoma or osteosarcoma. The main measure is anti-Müllerian hormone (AMH). Phase 3, 500 people. Randomized, blinded. Karolinska University Hospital (the registry lists the principal investigator as sponsor). 17 sites, Sweden. Recruiting. Started Mar 2023; primary completion Jan 2028 (est.). Record updated Oct 2023.
NCT06513962 Triptorelin started up to 14 days before or 7 days after chemotherapy begins, against chemotherapy alone, to protect the ovaries in adolescents and young adults with cancer. The main measures are enrollment, accrual and AMH levels. Phase 3, 60 people. Randomized, open label. Children's Oncology Group. 206 sites in Canada, United States. Recruiting. Started Feb 2025; primary completion Oct 2029 (est.). Record updated Aug 2026.
NCT05982093 Elacestrant alone, elacestrant with triptorelin (ovarian suppression), or tamoxifen, in premenopausal women with luminal breast cancer, to measure the biological activity of elacestrant with and without ovarian suppression. Phase 2, 96 people. Randomized, open label. SOLTI Breast Cancer Research Group. 15 sites, Spain. Recruiting. Started Feb 2023; primary completion Dec 2026 (est.). Record updated Apr 2026.

Triptorelin: puberty, endometriosis, bone and drug-formulation studies

Early puberty, endometriosis, bone loss in menopause, and a study of how a new triptorelin product is absorbed.

Recruiting and not-yet-recruiting trials: Triptorelin: puberty, endometriosis, bone and drug-formulation studies, from ClinicalTrials.gov, Nov 16, 2026
Registry record What it tests Design Sponsor, place and dates
NCT06487143 A 3-month triptorelin pamoate injection against 1-month triptorelin acetate injections in girls with idiopathic central precocious puberty. The main measure is the proportion with LH at or below 3 IU/L. Phase 4, 134 people. Not randomized, open label. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. 1 site, China. Not yet recruiting. Starts Jul 2024 (est.) (date has passed); primary completion Dec 2026 (est.). Record updated Jul 2024.
NCT06525155 Triptorelin (embonate) given three times or once in women with endometriosis cysts, to see how each schedule changes anti-Müllerian hormone (AMH). Phase 3, 32 people. Not randomized, open label. Rumah Sakit Pusat Angkatan Darat Gatot Soebroto. 1 site, Indonesia. Recruiting. Started Jan 2024; primary completion Feb 2025 (est.) (date has passed). Record updated Nov 2024.
NCT07254429 One triptorelin injection (Pamorelin 11.25 mg) to lower LH, against placebo, transdermal estrogen or transdermal testosterone, in women aged 40 to 65, to see how it changes bone remodeling after 8 weeks (COMPASS). Phase 2, 192 people. Randomized, placebo, blinded. Copenhagen University Hospital at Herlev (the registry lists the principal investigator as sponsor). 1 site, Denmark. Recruiting. Started Oct 2025; primary completion Dec 2027 (est.). Record updated Mar 2026.
NCT06683066 A bioequivalence study: how the body handles one 3.75 mg injection of a new triptorelin acetate product against Diphereline, measured in men with prostate cancer (Cmax and AUC). Phase 1, 120 people. Randomized, open label. The Affiliated Hospital of Qingdao University. 1 site, China. Recruiting. Started Dec 2024 (est.); primary completion Sep 2025 (est.) (date has passed). Record updated Nov 2024.

Triptorelin: prostate cancer

Triptorelin as androgen deprivation therapy with radiotherapy, tested against a shorter course or none. Prostate cancer trials that use triptorelin only as background are counted in the large-programs table.

Recruiting and not-yet-recruiting trials: Triptorelin: prostate cancer, from ClinicalTrials.gov, Nov 16, 2026
Registry record What it tests Design Sponsor, place and dates
NCT04242017 Salvage radiotherapy with 6 or 24 months of androgen deprivation therapy (triptorelin) in men whose prostate cancer returned after surgery. The main measure is metastasis-free survival. Phase 2/3, 394 people. Randomized, open label. Universitaire Ziekenhuizen KU Leuven. 3 sites, Belgium. Recruiting. Started Jul 2020; primary completion Feb 2026 (est.) (date has passed). Record updated Dec 2023.
NCT05019846 Salvage stereotactic radiotherapy (5 sessions) alone against the same radiotherapy plus triptorelin 22.5 mg, in men whose prostate cancer returned after surgery. The main measure is biochemical disease-free survival. Phase 3, 310 people. Randomized, open label. Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (the registry lists the principal investigator as sponsor). 1 site, Italy. Recruiting. Started Sep 2021; primary completion Dec 2025 (est.) (date has passed). Record updated Apr 2023.
NCT05557604 Stereotactic body radiotherapy alone against the same radiotherapy plus 6 months of androgen deprivation therapy (Decapeptyl) in unfavorable intermediate-risk or high-risk prostate cancer. The main measure is 3-year biochemical no-evidence-of-disease survival. Phase 2, 146 people. Randomized, blinded. Regina Elena Cancer Institute. 3 sites, Italy. Recruiting. Started Feb 2021; primary completion Feb 2024 (est.) (date has passed). Record updated Sep 2022.

Thymosin alpha-1 (thymalfasin)

The drug form is called thymalfasin. Fifteen of the 17 trials are run by hospitals or universities in China; one is in the United States and one in the United Arab Emirates. Most add it to cancer treatment. What the research shows.

Recruiting and not-yet-recruiting trials of Thymosin alpha-1 (thymalfasin), from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT05086614 Thymosin alpha-1 as add-on treatment after surgery for high-risk stage II and III colorectal cancer. Phase 3, 2,500 people. Randomized, blinded. Fudan University. 1 site, China. Recruiting. Started Apr 2021; primary completion Mar 2027 (est.). Record updated Oct 2021.
NCT07277439 Thymalfasin (thymosin alpha-1) with a PD-1 drug and chemoradiotherapy before surgery for stage III stomach or gastroesophageal junction cancer. Phase 2, 48 people. Randomized, open label. The First Affiliated Hospital with Nanjing Medical University. 1 site, China. Recruiting. Started Dec 2025; primary completion Feb 2027 (est.). Record updated Mar 2026.
NCT07675980 Thymosin alpha-1 or placebo for recurrent implantation failure (repeated failed embryo transfers) in IVF. Phase 2/3, 136 people. Randomized, placebo, blinded. Fakih IVF Fertility Center. 2 sites, United Arab Emirates. Recruiting. Started Feb 2026; primary completion Feb 2027 (est.). Record updated Nov 2026.
NCT06966687 Ulinastatin plus thymosin alpha-1 against ulinastatin alone after surgery for acute aortic dissection (PANDA XI). No drug phase, 200 people. Randomized, blinded. Nanjing Medical University. 4 sites, China. Enrolling by invitation. Started Apr 2025; primary completion Dec 2026 (est.). Record updated Jan 2026.
NCT07884201 Thymalfasin with chemotherapy and immunotherapy before surgery for triple-negative breast cancer. Phase 2, 572 people. Randomized, open label. Fudan University. No site listed yet. Not yet recruiting. Starts Nov 2026 (est.) (date has passed); primary completion Nov 2029 (est.). Record updated Oct 2026.
NCT06584006 Thymalfasin with interleukin-2 injections for low lymphocyte counts in people with blood cancers. Phase 2, 50 people. Randomized, open label. The First Affiliated Hospital of Xiamen University. 1 site, China. Recruiting. Started Sep 2024; primary completion Nov 2027 (est.). Record updated Sep 2024.
NCT06461910 A PD-1 antibody, thymalfasin and chemotherapy before surgery for stage III stomach or gastroesophageal junction cancer. Phase 2, 30 people. One group, open label. Zekuan Xu. 1 site, China. Recruiting. Started Jun 2024; primary completion Jan 2026 (date has passed). Record updated Mar 2026.
NCT06552598 An engineered cancer-killing virus (KD01) in gynecologic cancers. Thymalfasin is given with it in one group of the trial. Phase 1, 97 people. One group, open label. Tongji Hospital. 1 site, China. Recruiting. Started Apr 2024; primary completion Apr 2028 (est.). Record updated Jan 2026.
NCT06829355 Thymalfasin with regorafenib and tislelizumab in advanced colorectal cancer. Phase 2, 52 people. Randomized, open label. Beijing Friendship Hospital. 1 site, China. Recruiting. Started Feb 2025 (est.); primary completion Dec 2025 (est.) (date has passed). Record updated Feb 2025.
NCT07780721 Adebrelimab, thymalfasin and chemotherapy before surgery for esophageal cancer. Phase 2, 31 people. One group, open label. The Affiliated Hospital of Putian University. 1 site, China. Not yet recruiting. Starts Aug 2026 (est.) (date has passed); primary completion Aug 2028 (est.). Record updated Aug 2026.
NCT07644897 Thymosin alpha-1 with an anti-PD-1 antibody in older adults with advanced melanoma. Phase 2, 55 people. One group, open label. Sun Yat-sen University. 2 sites, China. Recruiting. Started May 2023; primary completion May 2027 (est.). Record updated Jun 2026.
NCT07382375 Treatment chosen by an AI-assisted immune subtype in acute aortic dissection. Thymalfasin is given to the subtypes with a weak immune response. No drug phase, 300 people. Randomized, blinded. Nanjing Medical University. 8 sites, China. Not yet recruiting. Starts Dec 2027 (est.); primary completion Dec 2027 (est.). Record updated Feb 2026.
NCT07103395 Chemotherapy, two checkpoint antibodies, radiotherapy and thymosin alpha-1 for locally advanced non-small cell lung cancer. Phase 2, 56 people. One group, open label. Sun Yat-sen University. 1 site, China. Recruiting. Started Jan 2026; primary completion Dec 2029 (est.). Record updated Jan 2026.
NCT06821100 Thymalfasin as a booster of the response to COVID-19 vaccine boosters in older adults. Phase 1, 75 people. Randomized, open label. The Methodist Hospital Research Institute. 1 site, United States. Recruiting. Started Dec 2024; primary completion Dec 2026 (est.). Record updated Jul 2026.
NCT06573398 Radiotherapy, chemotherapy, a PD-1 antibody and thymalfasin for borderline resectable pancreatic cancer. Phase 2, 20 people. One group, open label. Ruijin Hospital. No site listed yet. Not yet recruiting. Starts Sep 2024 (est.) (date has passed); primary completion Sep 2025 (est.) (date has passed). Record updated Aug 2024.
NCT07866118 Thymalfasin for immune recovery in adults with sepsis. No drug phase, 60 people. Randomized, blinded. Shanghai Zhongshan Hospital. 1 site, China. Recruiting. Started Oct 2026 (est.); primary completion May 2028 (est.). Record updated Oct 2026.
NCT07103408 Chemoradiotherapy, two checkpoint antibodies and thymosin alpha-1 for limited-stage small cell lung cancer. Phase 2, 56 people. One group, open label. Sun Yat-sen University. 1 site, China. Not yet recruiting. Starts Oct 2025 (est.) (date has passed); primary completion Sep 2029 (est.). Record updated Aug 2025.

Cerebrolysin

A mixture of small peptides from pig brain. Six of the eight trials are in people after a stroke. What the research shows.

Recruiting and not-yet-recruiting trials of Cerebrolysin, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT06897176 Cerebrolysin or placebo for language ability in people with non-fluent aphasia after a stroke. Phase 4, 40 people. Randomized, placebo, blinded. Yonsei University. 1 site, South Korea. Recruiting. Started Mar 2025; primary completion Jun 2025 (est.) (date has passed). Record updated Mar 2025.
NCT05821075 Prednisolone against cerebrolysin in people with Bell’s palsy. Phase 1/2, 90 people. Randomized, blinded. October 6 University. 1 site, Egypt. Recruiting. Started Aug 2023; primary completion Jan 2026 (est.) (date has passed). Record updated Jul 2025.
NCT06677502 Cerebrolysin or saline infusion in critically ill people with delirium. No drug phase, 500 people. Randomized, placebo, blinded. Medical University of Lublin. 1 site, Poland. Enrolling by invitation. Started Jan 2024; primary completion Jun 2025 (est.) (date has passed). Record updated Dec 2024.
NCT04427241 Cerebrolysin against a control group in people with prolonged disorders of consciousness. Phase 4, 12 people. Randomized, blinded. Konkuk University Medical Center. 1 site, South Korea. Recruiting. Started Jun 2023; primary completion Sep 2026 (est.) (date has passed). Record updated May 2026.
NCT07846488 Acupuncture-based rehabilitation after an ischemic stroke. Cerebrolysin and a B-vitamin complex are part of the combined treatment. No drug phase, 440 people. Randomized, blinded. National Hospital of Acupuncture, Vietnam. 1 site, Vietnam. Not yet recruiting. Starts Dec 2026 (est.); primary completion Jun 2028 (est.). Record updated Sep 2026.
NCT06339411 Cerebrolysin or saline placebo after clot removal (thrombectomy) for acute ischemic stroke. Phase 2, 100 people. Randomized, placebo, blinded. Chang Gung Memorial Hospital. No site listed yet. Not yet recruiting. Starts Sep 2026 (est.) (date has passed); primary completion Dec 2029 (est.). Record updated Aug 2026.
NCT06899464 A 14-day course of cerebrolysin against standard care, for safety and feasibility, in bleeding inside the brain (intracerebral hemorrhage). Phase 4, 30 people. Randomized, blinded. Cardinal Stefan Wyszynski University. No site listed yet. Not yet recruiting. Starts Oct 2025 (est.) (date has passed); primary completion Jan 2027 (est.). Record updated Mar 2025.
NCT07043686 Cerebrolysin added to standard rehabilitation after an acute ischemic stroke, against standard treatment alone. No drug phase, 30 people. Not randomized, blinded. University Medical Centre Ljubljana. 1 site, Slovenia. Recruiting. Started Jun 2025; primary completion Jul 2027 (est.). Record updated Jul 2025.

Retatrutide

The only recruiting record we could verify that names retatrutide as a treatment. ClinicalTrials.gov lists no other. What the research shows.

Recruiting and not-yet-recruiting trials of Retatrutide, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07165028 Tirzepatide or retatrutide against placebo in adults with fatty liver disease (MASLD), looking at health outcomes. Lilly’s master protocol called SYNERGY-Outcomes. Phase 3, 4,500 people. Randomized, placebo, blinded. Eli Lilly and Company. 563 sites in 34 countries and regions. Recruiting. Started Oct 2025; primary completion Aug 2030 (est.). Record updated Oct 2026.

Cagrilintide and CagriSema

All twelve are sponsored by Novo Nordisk. CagriSema is cagrilintide plus semaglutide. What the research shows.

Recruiting and not-yet-recruiting trials of Cagrilintide and CagriSema, from ClinicalTrials.gov, Nov 13, 2026
Registry record What it tests Design Sponsor, place and dates
NCT07817251 Whether adults with type 2 diabetes tolerate switching from semaglutide to CagriSema (cagrilintide plus semaglutide). Phase 3, 210 people. Randomized, blinded. Novo Nordisk A/S. 40 sites, United States. Recruiting. Started Sep 2026; primary completion Jun 2027 (est.). Record updated Sep 2026.
NCT07557953 How cagrilintide changes food intake and appetite, against placebo, in people with overweight or obesity. Phase 1, 120 people. Randomized, placebo, blinded. Novo Nordisk A/S. 1 site, Germany. Recruiting. Started Apr 2026; primary completion Apr 2027 (est.). Record updated May 2026.
NCT07282613 CagriSema against matching placebo for blood sugar and body weight in children and adolescents with type 2 diabetes. Phase 3, 80 people. Randomized, placebo, blinded. Novo Nordisk A/S. 58 sites in 10 countries and regions. Recruiting. Started Aug 2026; primary completion Sep 2029 (est.). Record updated Oct 2026.
NCT07597018 Blood levels of cagrilintide after repeated doses of different versions of it, in adults with overweight or obesity. Phase 1, 234 people. Randomized, placebo, open label. Novo Nordisk A/S. 1 site, Germany. Recruiting. Started May 2026; primary completion May 2027 (est.). Record updated Jun 2026.
NCT07919405 CagriSema, semaglutide, cagrilintide or placebo for high blood pressure in people with obesity. Phase 3, 1,408 people. Randomized, placebo, blinded. Novo Nordisk A/S. 212 sites in 19 countries and regions. Not yet recruiting. Starts Nov 2026 (est.) (date has passed); primary completion Jun 2028 (est.). Record updated Nov 2026.
NCT07010432 The effect of cagrilintide, alone or with semaglutide, on bone metabolism in people with obesity, against placebo. Phase 1, 144 people. Randomized, placebo, blinded. Novo Nordisk A/S. 1 site, Denmark. Recruiting. Started Jun 2025; primary completion May 2028 (est.). Record updated Sep 2026.
NCT07745504 Two versions of injectable cagrilintide against placebo in people with excess body weight. Phase 3, 285 people. Randomized, placebo, blinded. Novo Nordisk A/S. 36 sites in 6 countries and regions. Recruiting. Started Aug 2026; primary completion May 2027 (est.). Record updated Sep 2026.
NCT07411560 Weekly GIP with cagrilintide (an amylin analogue) and stomach-related side effects in people with overweight or obesity. Phase 1, 100 people. Randomized, placebo, blinded. Novo Nordisk A/S. 1 site, United Kingdom. Recruiting. Started Feb 2026; primary completion Jan 2027 (est.). Record updated Apr 2026.
NCT07527195 CagriSema, cagrilintide and semaglutide, and their effect on muscle health in people with obesity. Phase 1, 100 people. Randomized, placebo, blinded. Novo Nordisk A/S. 1 site, Denmark. Recruiting. Started Apr 2026; primary completion Apr 2028 (est.). Record updated May 2026.
NCT07607587 Tolerability of cagrilintide, against placebo, in people who could not tolerate GLP-1 drugs because of stomach side effects. Phase 1, 114 people. Randomized, placebo, blinded. Novo Nordisk A/S. 13 sites, United States. Recruiting. Started May 2026; primary completion Nov 2027 (est.). Record updated Oct 2026.
NCT07253285 Cagrilintide and CagriSema, against semaglutide and placebo, for weight in children and adolescents with excess body weight. Phase 3, 460 people. Randomized, placebo, blinded. Novo Nordisk A/S. 121 sites in 26 countries and regions. Recruiting. Started Jan 2026; primary completion Mar 2030 (est.). Record updated Sep 2026.
NCT07564414 Two doses of CagriSema against one dose of semaglutide for weight loss in people with obesity, with or without type 2 diabetes. Phase 3, 2,500 people. Randomized, blinded. Novo Nordisk A/S. 303 sites in 19 countries and regions. Recruiting. Started May 2026; primary completion Feb 2028 (est.). Record updated Sep 2026.

42 of the 118 rows show a start or primary completion date that has already passed. The registry says the study’s responsible party must update the primary completion date once it is reached (ClinicalTrials.gov), so these records may be out of date. We haven’t contacted anyone to check.

Not a trial: the registry also lists a testosterone spray sold under the Testagen brand, which isn’t the peptide. We left it out.

Large programs, linked rather than listed

These compounds are tested in many different conditions, so one list wouldn’t help you; the registry’s search lets you filter by condition and place. The counts are records that name the compound as a treatment and are recruiting, not yet recruiting or enrolling by invitation on Nov 13, 2026. The registry’s own search also matches related terms, so its count can be higher than ours.

Large trial programs, from ClinicalTrials.gov, Nov 13, 2026
Compound Records naming it as a treatment Of those, phase 3 Registry search
Semaglutide 212 48 Search the registry
Tirzepatide 125 19 Search the registry
Liraglutide 14 1 Search the registry
Methylene blue 19 4 Search the registry
Oxytocin in labor, delivery and cesarean care 26 2 Search the registry
Triptorelin as background hormone therapy 17 6 Search the registry

The oxytocin count is for Nov 15, 2026 and covers records that give oxytocin in labor, delivery and cesarean care. The oxytocin records outside obstetrics are listed above.

The triptorelin count is for Nov 16, 2026 and covers 17 records that name triptorelin only as one of several allowed hormone drugs, mostly in prostate cancer radiotherapy and drug trials, so triptorelin isn’t what they test. The 22 records that test triptorelin itself are listed above.

Compounds with no recruiting trial we found

We searched each compound on this site by name and by its other names. These had no recruiting, not-yet-recruiting or enrolling-by-invitation record that names them as a treatment: KPV, CJC-1295, Ipamorelin, Sermorelin, GHRP-2, GHRP-6, Hexarelin, IGF-1 LR3, IGF-1 DES, MGF, PEG-MGF, Follistatin-344, ACE-031, AOD-9604, HGH fragment 176-191, AICAR, BAM15, SLU-PP-332, 5-amino-1MQ, Tesofensine, FOXO4-DRI, Humanin, Selank, Semax, DSIP, Dihexa, Pinealon, PE-22-28, Enclomiphene, Melanotan 1, Argireline, SNAP-8, Syn-Ake, Pentapeptide-18, Pal-GHK, Syn-Coll, Nonapeptide-1, Cartalax, Testagen, Vilon, Cardiogen, Prostamax, Bronchogen, Vesugen, Cortagen, Chonluten, Ovagen, Pancragen, Thymalin, PT-141, GLOW, KLOW, ARA-290, LL-37, PNC-27, Dermorphin. That says nothing about older or finished trials, which we cover on each compound’s page.

Records we couldn’t verify

A sponsor called Hudson Biotech registered eight records between February 22 and March 14, 2026, all at one hospital in Shenzhen, China, with start dates within two weeks of each other, the same two contacts and no principal investigator named. Two of the eight call themselves an “example” in their own text, and one is titled “SURMOUNT-1,” the name of an Eli Lilly tirzepatide trial (sponsor search). We found no company website or other record of the sponsor. That isn’t proof the studies aren’t real. We list them here, and not above, until a named investigator, a posted protocol or results confirm them.

Eight records from one sponsor we could not verify, ClinicalTrials.gov, Nov 13, 2026
Registry record Compound What the record says
NCT07437547 BPC-157 for acute hamstring strain Phase 2, 120 people (recruiting)
NCT07437586 GHK-Cu gel for acute skin wounds Phase 2, 60 people (recruiting)
NCT07437560 Melanotan II with light therapy for vitiligo Phase 2, 60 people (recruiting)
NCT07505745 MOTS-c for insulin sensitivity in prediabetes Phase 2, 120 people (recruiting)
NCT07481734 Tesamorelin for fatty liver disease Phase 2, 120 people (recruiting)
NCT07467447 Retatrutide for obesity or overweight Phase 2, 300 people (recruiting)
NCT07487363 TB-500 for stable artery disease Phase 1/2, 80 people (recruiting)
NCT07481747 Tirzepatide, titled “SURMOUNT-1” Phase 3, 2,539 people (recruiting)

How we checked each record

  • We searched by name. Every compound on this site, under its other names too, such as LUM-201 for ibutamoren and thymalfasin for thymosin alpha-1.
  • We opened every record. It stays only if the compound is named in a treatment group. We dropped records that only measure it in the blood, follow people from an earlier trial, test a gene therapy, or test a different product with a similar name.
  • We checked who is behind it. Sponsor, sites, named investigators, and whether one sponsor registered several records at once.
  • We flagged old dates. A date that has passed is marked on the row.
  • We rechecked the numbers. Counts come from the registry on Nov 13, 2026 (kisspeptin, NAD+, glutathione and oxytocin: Nov 15, 2026; gonadorelin and triptorelin: Nov 16, 2026) and change daily.

Found a record we got wrong? Email editors@peptideresearchstudy.com.

Bring your questions to other researchers

Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.

Questions

Are there any BPC-157 clinical trials I can join?

One that we could verify: a trial at the University of Arkansas of 30 people recovering from rotator cuff repair surgery. It is not yet recruiting and is set to start in January 2027 (NCT07803250). A 120-person hamstring trial listed as recruiting comes from a sponsor we couldn’t verify, so we don’t count it.

Is a retatrutide trial recruiting?

Yes. Eli Lilly’s SYNERGY-Outcomes tests tirzepatide and retatrutide against placebo in 4,500 adults with fatty liver disease, at 563 sites in 34 countries and regions (NCT07165028). It is the only recruiting record we could verify that names retatrutide as a treatment. See what the research shows.

What does “recruiting” mean on ClinicalTrials.gov?

That participants are being recruited now, whether or not any have joined. “Not yet recruiting” means they are not being recruited yet, and “enrolling by invitation” means the team picks participants from a group it has already chosen (ClinicalTrials.gov, 2026).

Does a registered trial mean the peptide works?

No. A record says a trial is planned or running. A drug being studied in a trial hasn’t been proven safe or effective (Health Canada, 2026).

How do I find a peptide clinical trial near me?

Each row above lists where the trial runs. The registry’s search page lets you filter by condition and place (ClinicalTrials.gov). The trials above run in many countries, and some list no site yet.

Can I get a peptide by joining a trial?

Not reliably. Many of the trials above give some participants a placebo, the study team decides who qualifies, and participants follow the trial’s plan (Health Canada, 2026). Each record lists its rules for who can take part.

Sources

  1. ClinicalTrials.gov. Studies recruiting, not yet recruiting or enrolling by invitation that name each compound as an intervention; API v2 query and record-by-record review, Nov 13, 2026 (kisspeptin, NAD+, glutathione and oxytocin: Nov 15, 2026; gonadorelin and triptorelin: Nov 16, 2026). Registry
  2. UniProt. KiSS-1 metastasis-suppressor, human (Q15726): kisspeptin-10 is residues 112 to 121. UniProt entry
  3. ClinicalTrials.gov. Protocol Registration Data Element Definitions: Overall Recruitment Status and Primary Completion Date. ClinicalTrials.gov page
  4. Health Canada. Peptides: Research and clinical trials. Page dated October 23, 2026. Health Canada page
  5. ClinicalTrials.gov. Search for the sponsor Hudson Biotech, Nov 13, 2026: eight records. Sponsor search

Last reviewed Nov 13, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.